Optimizing the treatment of patients with multiple myeloma and renal impairment.

Optimizing the treatment of patients with multiple myeloma and renal impairment.

Item
http://www.wikidata.org/entity/Q38280032
Challenges in Analyzing the Biological Effects of ResveratrolPanobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updatePopulation pharmacokinetics of lenalidomide in multiple myeloma patients.Cancer Chemoprevention by Resveratrol: The p53 Tumor Suppressor Protein as a Promising Molecular Target.Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival.Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.
P2860

Optimizing the treatment of patients with multiple myeloma and renal impairment.

Item
http://www.wikidata.org/entity/Q38280032
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Optimizing the treatment of patients with multiple myeloma and renal impairment.
@en
type
label
Optimizing the treatment of patients with multiple myeloma and renal impairment.
@en
prefLabel
Optimizing the treatment of patients with multiple myeloma and renal impairment.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Optimizing the treatment of patients with multiple myeloma and renal impairment.
@en
P2093
P304
P31
P356
10.1016/J.CLML.2014.09.012
P407
P433
P478
P50
P577
P698